ASH Multiple Myeloma Meeting Spotlight

BCMA/CD19 dual-targeting FasTCAR-T cells showed a high objective response rate in a study of patients with newly diagnosed high-risk multiple myeloma.

Encouraging health-related quality of life benefit was demonstrated in for patients with transplant eligible, newly diagnosed multiple myeloma treated with a daratumumab quadruplet regimen.

In the CC-92480-MM-001, mezigdomide With dexamethasone demonstrated positive safety and efficacy in patients with heavily-pretreated multiple myeloma.

Positive results were reported on the phase 2 MagnetisMM-3 study at the ASH Annual Meeting 2022.

Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.

The use of 2 separate recommended phase 2 doses of Talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma.